Teva And Samsung Bioepis Enter Commercialization Agreement For OPUVIZ, A Biosimilar Referencing Eylea (aflibercept), In Canada

Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. today announced that the companies have entered into a license and commercialization agreement for OPUVIZ (aflibercept), a biosimilar referencing EYLEA1 (aflibercept), in Canada.

Under the agreement, Samsung Bioepis is responsible for registration and manufacture of the products, while Teva Canada (a subsidiary of Teva Pharmaceutical Industries Ltd.) is responsible for commercialization.

“This agreement is an important step in strengthening our biosimilars portfolio in Canada,” said Fabien Paquette, General Manager, Teva Canada. “It builds on our momentum in biosimilars, expands our ophthalmology footprint, and reflects our commitment to bringing high-quality treatment options to Canadian patients and healthcare professionals through strategic partnerships.”

“This agreement represents an important step in advancing our growth strategy in North America and expanding access of ophthalmic biologic medicines in Canada,” said Kwang Ryu, Vice President and Team Leader of Business Development at Samsung Bioepis. “Through our collaboration with Teva we are committed to expanding access to high-quality treatment options in Canada and helping more patients benefit from timely and sustainable care.”

OPUVIZ received Health Canada approval in October 2025 and is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment resulting from macular edema secondary to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO), diabetic macular edema (DME), and myopic choroidal neovascularization (mCNV).

Samsung Bioepis’ aflibercept biosimilar is also available in Europe and in Republic of Korea.

Teva Canada will provide further details on the anticipated Canadian market launch of OPUVIZ at the appropriate time.

About Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars, and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. For more information, visit www.tevapharm.com.

About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings, Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, endocrinology and neurology. For more information, visit www.samsungbioepis.com